AlloSource announces first patient enrolled in cartilage defect study

Thursday March 21, 2019 0 comments Tags: Centennial, AlloSource, ProChondrix CR, Ross Wilkins

CENTENNIAL -- AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, announced it enrolled the first patient in a study titled A Prospective, Multi-Center Study Evaluating ProChondrix® CR for the Repair of Focal Articular Cartilage Defects in the Knee.AlloSource_logoUSE

Chondral injuries impact more than one million patients across the United States annually and can cause compromised mobility and a decline in quality of life. AlloSource said its clinical study will evaluate the effectiveness of ProChondrix CR, a fresh cryopreserved osteochondral allograft, when used for cartilage defects in the knee.

AlloSource said it developed ProChondrix CR as a cost-effective, single-stage alternative to provide the necessary components for articular cartilage restoration. 

Following cryopreservation, ProChondrix CR delivers high chondrocyte viability for up to two years (~94% avg.) and helps stimulate hyaline cartilage growth by providing live, functional cells and other biological components necessary for the repair and regeneration of damaged cartilage tissues.

The extracellular matrix provides structural support for cell migration and proliferation along the graft-native tissue line promoting integration, while viable chondrocytes aid in cartilage repair by generating proteins that help promote chondrogenesis, the company said.

"This study and our clinical efforts underscore the ongoing need for a long-term solution for patients with cartilage damage," said Ross Wilkins, AlloSource senior medical director.

"Providing advanced biologic solutions, like ProChondrix CR, to support patient healing is what motivates us every day. This is an important milestone for AlloSource as we advance our investment in the clinical use of tissue."

AlloSource said it is excited to partner with its research sites to focus on the long-term outcomes of using ProChondrix CR for the repair of symptomatic articular cartilage defects on the femoral condyle and the patella.